Business Context and Reporting Period
Zevra Therapeutics, Inc. (ZVRA) filed a Form 8-K on March 11, 2025, to announce financial results for the fourth quarter and fiscal year ended December 31, 2024. The company is a Delaware corporation headquartered in Celebration, Florida, with common stock listed on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not detailed in the body of this 8-K report.
Material Changes and Unusual Items
- Restatements: The filing includes forward-looking statements regarding the estimated extent and impacts of financial restatements.
- Internal Controls: Management has issued conclusions regarding the Company's internal control over financial reporting, disclosure controls and procedures, and the existence of any material weakness.
- Filing Delays: The report addresses the timing of the filing of the 2024 Form 10-K.
Guidance, Outlook, and Risks
The document contains a cautionary statement concerning forward-looking statements. These include expectations about the restatement process, the 2024 Form 10-K filing timeline, and internal control assessments. The company disclaims any obligation to update these statements and notes that actual results may differ materially due to risks detailed in its 2023 Form 10-K and 2024 Form 10-Q.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2024 financial figures.
- Verify the scope and impact of the mentioned financial restatements.
- Confirm the status of the material weakness in internal controls and the expected filing date for the 2024 Form 10-K.
- Assess liquidity position and cash runway given the context of restatements and potential operational impacts.